Press Release

 

BioPharmX Reports Fiscal First Quarter 2020 Financial Results

SAN JOSE, Calif., June 11, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the quarter ended April 30, 2019.

Recent Highlights

·

Completed the last patient visit in the Phase 2b clinical trial of BPX-041, a novel topical gel formulation of fully solubilized minocycline for the treatment of papulopustular rosacea. The company anticipates announcing topline efficacy and safety data from the study in early July 2019 pending database lock and results validation.

·

Raised net proceeds of $3.6 million from the sale of common stock in a registered direct offering.

·

Regained compliance with NYSE American continued listing standards related to the company’s low stock price by effecting a 1-for-25 reverse stock split.

·

Entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC whereby the company may issue common stock for proceeds up to $8.5 million from time to time through “at the market offerings.”

·

Further reduced operating costs by reducing its workforce by approximately 20%.

“The company continues to take steps on behalf of its shareholders to advance and to drive value in its topical minocycline programs.” said Dr. Tierney, BioPharmX CEO. “As such, we are looking forward to communicating the topline results from our Phase 2b rosacea study.” 

First Quarter Financial Results

For the first quarter ended April 30, 2019, total operating expenses were $3.6 million, compared with total operating expenses of $4.4 million in the prior fiscal year's first quarter.

Net loss for the quarter ended April 30, 2019 was $3.6 million, or $0.38 per share, compared with a net loss of $4.4 million, or $0.61 per share, during the prior fiscal year's first quarter. 

Excluding stock-based compensation expense and the impact of change in fair value of warrant liability, non-GAAP net loss for the quarter ended April 30, 2019 was $3.4 million, or $0.36 per share. During the first quarter of the prior fiscal year, the comparable non-GAAP net loss was $3.7 million, or $0.52 per share.

Cash and cash equivalents, as of April 30, 2019, were $3.3 million. 

About BioPharmX® Corporation
BioPharmX Corporation (NYSE American: BPMX) is a specialty pharmaceutical company focused on developing prescription products utilizing its proprietary HyantX Topical Delivery System for dermatology indications. To learn more about BioPharmX, visit www.BioPharmX.com.

Use of Non-GAAP Measures
BioPharmX Corporation has supplemented its financial information prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) with non-GAAP measures, including non-GAAP net loss and non-GAAP net loss per share, which do not include stock-based compensation expense and the impact of changes in fair value of warrant liability. The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance

 

 

 

with GAAP. Management uses the non-GAAP information internally to evaluate its ongoing business, operational performance and cash requirements and believes these non-GAAP measures are useful to investors as they provide the same basis for evaluating BioPharmX Corporation's performance as applied by management.

BioPharmX Corporation has provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure. These non-GAAP measures may be different from non-GAAP measures used by other companies, including peer companies, and therefore, comparability may be limited. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. BioPharmX Corporation believes that non-GAAP measures have limitations in that they do not reflect all of the amounts associated with its results of operations as determined in accordance with GAAP and that these measures should be considered in addition to, not as a substitute for or in isolation from, measures prepared in accordance with GAAP. BioPharmX Corporation encourages investors and others to review the company's financial information in its entirety and not rely on a single financial measure.

Stock-based compensation expense represents non-cash charges related to equity awards granted by BioPharmX Corporation. The change in fair value of warrant liability results from the periodic revaluing of the warrant liability. These amounts are excluded from the company’s non-GAAP net loss and non-GAAP net loss per share because they are not reflective of ongoing operating results in the period incurred. Although these may be recurring charges to BioPharmX Corporation's operations, management believes the measurement of these amounts can vary considerably from period to period and depend substantially on factors that are not a direct consequence of operating performance that is within management's control. Thus, management believes that excluding these charges from non-GAAP net loss and non-GAAP net loss per share facilitates comparisons of BioPharmX Corporation's operational performance in different periods, as well as with similarly determined non-GAAP financial measures of comparable companies.

Forward-Looking Statement
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's expectations, plans, intentions, and strategies, including, but not limited to the timing to complete the Phase 2b study for BPX-04, the topline results from the company’s Phase 2b rosacea study, the company’s ability to raise capital under its Capital On Demand Sales Agreement, the commencement and results of future trials for BPX-04, level of operating expenditures, the company's ability to obtain patent protection and defend its intellectual property and the company's ability to regain compliance with the NYSE American LLC’s continued listing standards and maintain its listing in the future. Additional risks are set forth in our filings with the Securities and Exchange Commission, including those described in the company's Quarterly Report on Form 10-Q for the quarter ended April 30, 2019. The forward-looking statements included in this press release are made only as of the date hereof, and the company undertakes no obligation to publicly update such statements.

1Caution: BPX-04 is a new drug limited by the U.S. law to investigational use only.

BioPharmX and HyantX are registered trademarks of BioPharmX, Inc.

For further information:

 

Media Contact

investors@biopharmx.com

 

 

--TABLES TO FOLLOW --

 

 

BIOPHARMX CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except per share amounts; unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

 

 

 

 

 

April 30,

 

 

 

 

 

 

 

 

2019

 

2018

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues, net

 

$                -  

 

$              18

 

 

 

 

Cost of goods sold

                  -  

 

                  7

 

 

 

 

Gross margin

 

                  -  

 

                11

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

            2,199

 

           2,327

 

 

 

 

 

Sales and marketing

               264

 

              601

 

 

 

 

 

General and administrative

            1,177

 

           1,446

 

 

 

 

 

 

Total operating expenses

            3,640

 

           4,374

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

           (3,640)

 

         (4,363)

 

 

 

 

Change in fair value of warrant liability

                   9

 

              (66)

 

 

 

 

Other income, net

                 10

 

                29

 

 

 

 

 

Loss before provision for income taxes

           (3,621)

 

         (4,400)

 

 

 

 

 

Provision for income taxes

                   2

 

                  2

 

 

 

 

Net and comprehensive loss

$         (3,623)

 

$       (4,402)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share

 

 

 

 

 

 

 

 

Basic and diluted

($0.38)

 

($0.61)

 

 

 

 

Shares used in computing net loss per share

 

 

 

 

 

 

 

 

Basic and diluted

            9,433

 

           7,189

 

 

 

 

 

 

 

 

 

 

BIOPHARMX CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, unaudited)

 

 

 

 

 

 

 

 

 

 

 

April 30,

 

January 31,

 

 

 

 

2019

 

2019

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

$          3,283

 

$         3,069

 

 

Prepaid expenses and other

               250

 

              316

 

 

 

Total current assets

            3,533

 

           3,385

 

 

 

 

 

 

 

 

Property and equipment, net

               140

 

              148

 

Operating lease right-of-use asset

            1,136

 

                       —

 

Other

 

               121

 

              121

 

 

 

Total assets

$          4,930

 

$         3,654

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

Current liabilities:

 

 

 

 

 

Accounts payable

$          1,185

 

$         1,363

 

 

Accrued expenses and other

            1,346

 

              934

 

 

 

Total current liabilities

            2,531

 

           2,297

 

 

 

 

 

 

 

 

Long-term liabilities

               975

 

                59

 

 

 

Total liabilities

            3,506

 

           2,356

 

 

 

 

 

 

 

 

Stockholders' equity

            1,424

 

           1,298

 

 

 

Total liabilities and stockholders’ equity

$          4,930

 

$         3,654

 

 

 

 

BIOPHARMX CORPORATION

Reconciliation of GAAP Net Loss to Non-GAAP Net Loss

(in thousands, except per share amounts; unaudited)

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

 

April 30,

 

 

 

 

2019

 

2018

 

 

 

 

 

 

 

 

GAAP net loss available to common stockholders

$         (3,623)

 

$       (4,402)

 

 

 

 

 

 

 

 

 

Change in fair value of warrant liability

                  (9)

 

                66

 

 

Stock-based compensation expense:

 

 

 

 

 

-

Research and development

               103

 

              200

 

 

-

Sales and marketing

                 21

 

              129

 

 

-

General and administrative

                 67

 

              264

 

 

 

Total stock-based compensation expense

               191

 

              593

 

 

Total reconciling items

               182

 

              659

 

Non-GAAP net loss available to common stockholders

$         (3,441)

 

$       (3,743)

 

 

 

 

 

 

 

 

GAAP net loss available to common stockholders

$           (0.38)

 

$         (0.61)

 

 

Reconciling items

 

 

 

 

 

-

Change in fair value of warrant liability

                         —

 

             0.01

 

 

-

Stock-based compensation expense

              0.02

 

             0.08

 

 

 

 

 

 

 

 

Non-GAAP net loss per share: basic and diluted

$           (0.36)

 

$         (0.52)

 

 

 

 

 

 

 

 

Shares used in computing non-GAAP net loss per share

 

 

 

 

 

Basic and diluted

            9,433

 

           7,189

 

View differences made from one to another to evaluate Biopharmx Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Biopharmx Corp.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account